Hematopoietic and Lung Platelet Biogenesis as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis (IPF)

Introduction

A recent study indicated that, in mice, the lung harbors megakaryocytes and is a site of platelet biogenesis (1). The presence of megakaryocytes has also been reported in human lungs (2, 3); however, the characteristics and role of lung megakaryocytes in homeostatic conditions, as well as chronic lung diseases such as idiopathic pulmonary fibrosis (IPF), are not well understood.

We investigated whether megakaryocyte/platelet gene signatures are altered in IPF by analyzing publicly available transcriptome datasets with xCell (4), a novel computational method. We further sought to determine whether platelet counts and mean platelet volume (MPV) in peripheral blood, two platelet parameters routinely measured in clinical practice (as a part of complete blood count [CBC]), are associated with lung transplant-free survival in our own IPF cohort.

Methods

We analyzed the following NCBI Gene Expression Omnibus (GEO) transcriptome datasets from IPF patients and healthy controls: lung tissue (GSE47460_GPL6480, GSE47460_GPL14550), bronchoalveolar lavage (BAL) cells (GSE70867), and peripheral whole blood (GSE33566, GSE93606). We generated gene enrichment scores for megakaryocytes and platelets with xCell, a computational method that assesses enrichment of individual cell types based on gene expression profile, and compared the scores between IPF patients and controls using unpaired t-test or Mann-Whitney test. In GSE70867 and GSE93606 (where survival data were available), we compared event-free survival between patients with higher enrichment scores (above the median) and patients with lower enrichment scores (below the median) using a log-rank test.

We also analyzed data from our own Tulane IPF cohort to determine whether platelet counts and MPV in peripheral blood are associated with lung transplant-free survival. We performed Cox proportional hazards regression analysis, adjusting for age, sex, forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO). This study was approved by the Tulane University Institutional Review Board. A p-value <0.05 was considered statistically significant.

Results

In lung tissue, samples from IPF patients had significantly lower megakaryocyte enrichment scores than controls (i.e., IPF lung transcriptome was significantly less enriched with a megakaryocyte gene signature than the control lung transcriptome) (Figure 1A). Platelet scores were not significantly different between IPF lung transcriptome and control lung transcriptome. In BAL cells, IPF patients had significantly lower platelet scores than controls, and IPF patients with lower platelet scores had significantly worse lung transplant-free survival rates than IPF patients with higher scores (log-rank test p<0.0001, hazard ratio=2.190 [95% CI: 1.476–3.249]) (Figure 1B). In contrast, in peripheral whole blood, IPF patients had significantly higher megakaryocyte scores than controls, and IPF patients with higher megakaryocyte scores had significantly worse disease progression-free survival (i.e., survival without significant [>10%] decline in FVC over six months) than IPF patients with lower megakaryocyte scores (log-rank test p=0.0096, hazard ratio=2.535 [95% CI: 1.254–5.128]) (Figure 1C). Platelet scores were not significantly different between IPF blood transcriptome and control blood transcriptome.

• Download figure
• Open in new tab

Figure 1. Megakaryocyte/platelet gene signatures were altered in IPF in a compartment-specific manner.

We analyzed IPF transcriptome datasets available in NCBI Gene Expression Omnibus (GEO). We generated gene enrichment scores for megakaryocytes and platelets with xCell (https://xcell.ucsf.edu/), a novel computational method that assesses enrichment of individual cell types based on gene expression profile.

(A) In lung transcriptome (GSE47460_GPL6480, GSE47460_GPL14550), IPF patients had significantly lower megakaryocyte enrichment scores than controls (who underwent surgery for the investigation of a nodule but had no chronic lung disease by CT or pathology).

(B) In BAL cell transcriptome (GSE70867), IPF patients had significantly lower platelet enrichment scores than controls (Left: Freiburg cohort only, for which controls were available). IPF patients with lower platelet scores (i.e., lower than median) had significantly worse lung transplant-free survival than IPF patients with higher platelet scores (i.e., higher than median) (log-rank test p<0.0001, hazard ratio=2.190 [95% CI: 1.476–3.249]) (Right: overall cohort [=Freiburg, Siena, and Leuven cohort]).

(C) In peripheral whole blood transcriptome (GSE33566, GSE93606), IPF had significantly higher megakaryocyte scores than age- and sex-matched healthy controls (Left, middle). IPF patients with higher megakaryocyte scores (above the median) had worse disease progression-free survival* than IPF patients with lower megakaryocyte scores (below the median) (log-rank test p=0.0096, hazard ratio=2.535 [95% CI: 1.254–5.128]) (Right).

*Disease progression-free survival was defined as survival without significant [>10%] decline in FVC over six months.

(D) Working hypothesis (proposed schema): Altered megakaryocyte/platelet biogenesis in IPF

In our Tulane IPF cohort (n=184; Table 1), univariate analysis revealed that higher MPV (but not higher platelet count) was significantly associated with worse lung transplant-free survival (p=0.042). More importantly, multivariate analysis revealed that higher MPV (but not higher platelet count) was significantly associated with worse lung transplant-free survival, independent of age, sex, FVC, and DLCO (p=0.031) (Multivariate analysis 1, 2). Furthermore, higher MPV was significantly associated with worse lung transplant-free survival, independent of age, sex, FVC, DLCO, and platelet counts (p=0.012) (Multivariate Analysis 3).

Discussion

Our analysis revealed that megakaryocyte/platelet gene signatures were altered in IPF in a compartment-specific manner. Based on our findings, one could speculate that IPF lungs harbor fewer (healthy) megakaryocytes due to their altered megakaryocyte niche and that megakaryocytes are actually decreased in IPF lungs. So far, published single-cell RNA-seq analyses have failed to identify a cluster of lung megakaryocytes in fibrotic lung tissue (5, 6). This may be because lung megakaryocytes are too rare or fragile to be isolated without any enrichment or a special protocol optimized for megakaryocytes.

There are a few possible explanations for less enrichment of megakaryocyte gene signature in IPF lung transcriptome and more enrichment of megakaryocyte gene signature in IPF blood transcriptome compared to control counterparts (Figure 1D). One possibility is that decreased megakaryocyte/platelet biogenesis in IPF lungs induces megakaryocyte/platelet biogenesis in bone marrow. For example, bone marrow may be producing more megakaryocytes and/or releasing more megakaryocytes into the circulation in response to factors released by fibrotic lungs. The second possibility is that megakaryocytes cannot remain in the altered niche within IPF lungs and therefore escape into the circulation. The third possibility is that fibrotic lungs are “educating” circulating platelets and modifying their transcriptome, as shown in previous works on “tumor-educated platelets” (7).

There are notable limitations to our study. One major limitation is that in silico prediction/estimation of gene signature enrichment for various types of cells in tissues is still far from perfect. Another limitation is that a megakaryocyte gene signature derived from bone marrow megakaryocytes is unlikely to be fully applicable to lung megakaryocytes, because lung megakaryocytes are transcriptionally (and phenotypically) distinct from bone marrow megakaryocytes. For example, lung megakaryocytes have higher expression of MHC class II and other molecules related to antigen presentation compared to bone marrow megakaryocytes (1, 8, 9). Furthermore, the prognostic utility of platelet gene signature in BAL cells, megakaryocyte gene signature in blood, and MPV in blood needs to be confirmed in other validation cohorts. Lastly, our study did not answer the following important questions: 1) Do megakaryocytes and/or platelets contribute to the pathogenesis of IPF? 2) Is the human lung a reservoir of megakaryocyte progenitors and a source of platelet biogenesis, as observed in mouse lungs? Further studies are needed to address these questions.

In conclusion, megakaryocyte/platelet gene signatures are altered and may have prognostic value in IPF. Moreover, MPV, a platelet parameter routinely measured in clinical practice, may be a simple yet novel prognostic biomarker in IPF. Further studies are needed to elucidate megakaryocyte/platelet biogenesis and to validate prognostic utility of megakaryocyte/platelet gene signatures as well as MPV in IPF.